We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Centessa Pharmaceuticals plc (CNTA) ADS EACH REPR 1 ORD SHS

Sell:$12.01 Buy:$12.07 Change: $0.71 (5.58%)
Market closed |  Prices as at close on 6 December 2021 | Switch to live prices |
Sell:$12.01
Buy:$12.07
Change: $0.71 (5.58%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Market closed |  Prices as at close on 6 December 2021 | Switch to live prices |
Sell:$12.01
Buy:$12.07
Change: $0.71 (5.58%)
Market closed |  Prices as at close on 6 December 2021 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Centessa Pharmaceuticals plc (Centessa), formerly Centessa Pharmaceuticals Limited, is a pharmaceutical company. The Company's asset-centric programs range from discovery-stage to late-stage development and include diverse therapeutic areas such as oncology, hematology, immunology/inflammation, neuroscience, hepatology, pulmonology and nephrology. Its portfolio consists of approximately 16 conviction programs, including four programs evaluated in clinical trials and 12 additional preclinical programs. Centessa's clinical stage product candidates include Lixivaptan, SerpinPC, Imgatuzumab and ZF874. The Company's preclinical assets include ZF887, MGX292, CBS001, CBS004, LB1, LB2, Oral OX2R Agonist, Intranasal OX2R Agonist, Dual STAT3/5 Degrader, EGFR Ex20 Inhibitor, EGFR-C797S Inhibitor and EGFR Inhibitors. The Company's subsidiaries include ApcinteX, Capella BioScience, Janpix, LockBody, Morphogen-IX, Orexia Therapeutics, Palladio Biosciences, PearlRiver Bio, PegaOne and Z Factor.

Contact details

Address:
3Rd Floor, 1 Ashley Road
CAMBRIDGE
WA14 2DT
United Kingdom
Telephone:
+ ()
Website:
https://www.centessa.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CNTA
ISIN:
US1523091007
Market cap:
$1.14 billion
Shares in issue:
179.80 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.